Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: rli123 who wrote (3477)	12/14/2000 10:28:02 AM
From: Tatnic	Read Replies (1) \| Respond to of 5582

In my opinion, and its based on my gut feel and not any real due diligence, is that nicotine gum could be a much better revenue generator than their cold medicine. When I go to the pharmacy I see a pile of cold remedies vying for attention on the shelves...I honestly don't see how zicam can grab market share (or any significant share for that matter) in that highly competitive, fad driven market. I could be wrong...but nicotine gum, that to me is a different story altogether.